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Efficient 18F-Labeling of Large 37-Amino Acid pHLIP Peptide
Analogues and their Biological Evaluation
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Abstract
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Solid tumors often develop an acidic microenvironment, which plays a critical role in tumor
progression and is associated with increased level of invasion and metastasis. The 37-residue pH
(low) insertion peptide (pHLIP®) is under study as an imaging platform because of its unique
ability to insert into cell membranes at a low extracellular pH (pHe<7). Labeling of peptides with
[18F]-fluorine is usually performed via prosthetic groups using chemoselective coupling reactions.
One of the most successful procedures involves the alkyne-azide copper(I) catalyzed cycloaddition
(CuAAC). However, none of the known “click” methods have been applied to peptides as large as
pHLIP. We designed a novel prosthetic group and extended the use of the CuAAC “click
chemistry” for the simple and efficient 18F-labeling of large peptides. For the evaluation of this
labeling approach, a D-amino acid analogue of WT-pHLIP and a L-amino acid control peptide KpHLIP, both functionalized at the N-terminus with 6-azidohexanoic acid, were used. The novel 6[18F]fluoro-2-ethynylpyridine prosthetic group, was obtained via nucleophilic substitution on the
corresponding bromo-precursor after 10 min at 130 °C with a radiochemical yield of 27.5 ± 6.6%
(decay corrected) with high radiochemical purity ≥ 98%. The subsequent CuI catalyzed “click”
reaction with the azido functionalized pHLIP peptides was quantitative within 5 min at 70 °C in a
mixture of water and ethanol using Cu-acetate and sodium L-ascorbate. [18F]-D-WT-pHLIP and
[18F]-L-K-pHLIP were obtained with total radiochemical yields of 5–20% after HPLC
purification. The total reaction time was only 85 min including formulation. In vitro stability tests
revealed high stability of the [18F]-D-WT-pHLIP in human and mouse plasma after 120 min, with
the parent tracer remaining intact at 65 and 85%, respectively. PET imaging and biodistribution
studies in LNCaP and PC-3 xenografted mice with the [18F]-D-WT-pHLIP and the negative
control [18F]-L-K-pHLIP revealed pH-dependent tumor retention. This reliable and efficient
protocol promises to be useful for the 18F-labeling of large peptides such as pHLIP and will
accelerate the evaluation of numerous [18F]-pHLIP analogues as potential PET tracers.
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INTRODUCTION
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Positron Emission Tomography (PET) is a non-invasive functional in vivo imaging
modality, commonly used in tumor diagnosis. Tremendous effort has been made towards the
development of additional efficient and widely applicable PET tracers, given the limitations
of [18F]-FDG, for the targeting of a large variety of cancers. However, the development of a
universal tumor targeting PET tracer is limited due to tumor heterogeneity and differences
within the tumor environment.1 Therefore, targeting a physiological anomaly present in
most cancers seems very promising for the development of a widely applicable diagnostic
agent in oncology. The acidity of the tumor microenvironment is one of such anomalies,
which plays a significant role in progression and is often associated with increased invasion
and metastasis.2 It is present in 90% of tumor microenvironments and is therefore
considered a promising environmental marker for targeting.3, 4

$watermark-text

A 37-residue peptide discovered in 1997 by Hunt et al.5 was recently shown to display
unique pH-dependent properties: the pH Low Insertion Peptide (WT-pHLIP, NH2ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTG-CO2H) is soluble in aqueous
solution at physiological pH and shows transient interaction with cell membranes in tissues
with neutral extracellular pH (pHe). In tissues with an acidic pHe, Asp/Glu residues of
pHLIP are protonated, which increases the overall hydrophobicity of the peptide and affinity
to the cell membrane. As a result, pHLIP inserts and translocates itself through the
phospholipid bilayer that is the cellular membrane.6 This insertion involves a change in the
peptide conformation to a α-helix, the N-terminus remaining in the extracellular space,
while the C-terminus reaches the intracellular lumen.
The pHLIP peptide was recognized as a potentially useful platform for tissue acidity
imaging and therefore, its potential application as a universal tool in oncology was
envisaged.7 We successfully demonstrated that fluorescent pHLIP could be used to detect
tissue acidity and target tumors in mice.8 In an extension to the study, 64Cu-labeled pHLIP
was evaluated for its suitability as a PET tumor imaging agent. The novel tracer displayed
good imaging characteristics with the highest level of radioactivity accumulation in LNCaP
tumor being reached 1 h after administration, but some demetallation9 and a significant
retention of activity in the GI tract were also observed.

$watermark-text

Fluorine-18 is the most common PET nuclide due to its favorable physical properties (low
positron energy, pure positron decay and 110 min half-life), availability, and dosimetry.10, 11
Therefore, the 18F-nuclide was considered the ideal non-metal based alternative for the PETlabeling of pHLIP and its analogues. However, the 18F-labeling of large peptides such as
WT-pHLIP (molecular weight (MW) > 4000 Da) still remains challenging because
nucleophilic substitution with [18F]-fluoride requires harsh basic conditions and cannot be
performed directly on peptides.12 as a result, numerous approaches to label peptides
with 18F were developed, including bioconjugation with prosthetic groups like Nsuccinimidyl-4-[18F]fluorobenzoate ([18F]SFB) or p-nitrophenyl-2-[18F]fluoropropionate
([18F]NFP),13 or more recent methodologies involving Al18F chelation14 or the “less
conventional” use of organosilicon-based fluoride acceptor.15 Among the recent
chemoselective 18F-labeling strategies involving indirect labeling by means of [18F]prosthetic groups, the popular alkyne-azide copper(I) catalyzed cycloaddition (CuAAC)
“click” reaction, where the coupling of an azide and an alkyne leads to the formation of a
triazole ring, appeared well suited for our purpose. It has been shown to be widely
applicable and efficient for the labeling of peptides, mostly requiring a two-step synthetic
approach. The success of this strategy and its wide range of application led to the
development of a large variety of 18F-labeled prosthetic groups as exemplified on Figure 1
and recently reviewed.16,17 Thus, the one-step radiolabeling of suitable precursors followed

Bioconjug Chem. Author manuscript; available in PMC 2013 August 15.

Daumar et al.

Page 3

by cycloaddition of the resulting 18F-bearing alkyne prosthetic groups with azido
functionalized peptides of interest was shown to result in total RCYs of 20 – 75% (d.
c.).18–20 The corresponding radiosyntheses utilizing an 18F-labeled azido prosthetic group
and an alkyne functionalized peptide were shown to be equally efficient.21–23
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With regards to the radiochemistry however, only a few of the common 18F-labeled
prosthetic groups like 1-(azidomethyl)-4-[18F]-fluorobenzene24 or 4-[18F]fluoro-N-methylN-(prop-2-ynyl)-benzenesulfonamide,20 are UV-detectable. A common disadvantage of
[18F]-fluoroalkynes or azides is also their high volatility, which can be technically
challenging.13, 18, 19, 21, 25 Finally, the preparation of [18F]-glycosylazides or azidomethyl[18F]-benzenes for example involves more than one step and is therefore more laborious.22
Besides these inherent difficulties of a prosthetic group radiosynthesis, to the best of our
knowledge, only Hausner et al. have demonstrated an efficient 18F-radiolabeling of peptides
with a high molecular weight (MW > 2000 Da), commenting on the increasing challenge to
label peptides with increasing complexity and size.13 Ramenda et al. have reported the 18Fradiolabeling of azide-functionalized Human Serum Albumin but noted that the introduction
of azide residues into HSA and subsequent radiolabeling via click chemistry significantly
altered the structural and functional integrity of HSA.20 More recently, in an eloquent
approach, Gill et al. have demonstrated the utility of maleimide functionalized alkyne in
labeling antibodies with [18F]-fluorine via a click approach.26 However, the presence of
cysteine and lysine residues in the pHLIP amino acid sequence makes this approach
unrealistic in our case, as it is necessary to limit the number of derivatization sites to one in
order to preserve the unique pHLIP properties. Therefore, it appears that further
efficient 18F-labeling procedures are necessary for the development of a successful and
widely applicable [18F]-pHLIP derivative.
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Herein we report on the use of a novel 18F-labeled prosthetic group for the efficient two-step
“click” radiolabeling of azidohexanoic acid derivatized pHLIP involving a UV-detectable
prosthetic group. The ultimate aim of this study was to evaluate the novel prosthetic group
for its universal utilization in [18F]-peptide chemistry. Therefore, the reaction conditions
were investigated with two different peptides: D-WT-pHLIP (all amino acids have D
configuration) and L-K-pHLIP (all amino acids have L configuration), which has the exact
same sequence as WT-pHLIP but two aspartic acid residues have been replaced with
lysines. These aspartic acid residues are present in the transmembrane part after insertion
and are critical for pH dependent behavior. Therefore L-K-pHLIP lacks pH-dependent
behavior and was used as a negative control in our study.6, 27, 28 In vitro stability of the
[18F]-D-WT-pHLIP in both human and murine plasma was also examined. Finally, PET
imaging and biodistribution studies were performed in order to determine the in vivo
properties of the novel [18F]-pHLIP conjugates in LNCaP and PC-3 tumor xenografts
bearing mice.

MATERIALS and METHODS
General methods
All chemicals and solvents were purchased from Sigma-Aldrich, Anichem or Fluka and
were used without further purification unless specifically stated otherwise. All peptide
starting materials were purchased from C S Bio Co. (Menlo Park, CA, USA). Ultra-pure
water was used in this work (>18 MΩcm−1 at 20 ºC, Milli-Q, Millipore, Billerica, MA,
USA). All instruments were maintained and calibrated regularly according to quality control
procedures as previously reported. Thin layer chromatography performed on pre-coated
silica gel 60 F245 aluminium sheets suitable for UV detection of compounds was used for
monitoring the reactions. Radioactivity measurements were performed with a Capintec
CRC1243 Dose Calibrator (Capintec, Ramsay, NJ, USA). Precise quantification of low
Bioconjug Chem. Author manuscript; available in PMC 2013 August 15.
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radioactivity samples was achieved with a Perkin Elmer (Waltham, MA, USA) Automatic
Wizard2 Gamma Counter. Nuclear magnetic resonance spectra were recorded on a Bruker
AVIII 500.13 MHz spectrometer with an internal standard from solvent signals. Chemical
shifts are given in parts per million (ppm) relative to tetramethylsilane (0.00 ppm). Values of
the coupling constant, J, are given in hertz (Hz). The following abbreviations are used for
the description of 1H NMR and 13C NMR spectra: singlet (s), doublet (d), doublet of
doublets (dd), triplet (t), quartet (q). The chemical shifts of complex multiplets are given as
the range of their occurrence. Low resolution mass spectra (LRMS) were recorded with a
Waters Acquity UPLC with electrospray ionization SQ detector (ESI). High resolution mass
spectra (HRMS) were recorded with a Waters LCT Premier system (ESI) and MALDI TOF
analysis was performed on a Bruker Ultraflex TOF/TOF MALDI tandem TOF mass
spectrometer. Quality control and purification of the final products in order to confirm the
purity ≥ 95% of the radioactive intermediates and final products were achieved by analytical
or semipreparative high performance liquid chromatography (HPLC). All HPLC
experiments were performed on a Shimadzu HPLC system equipped with a Flow Count PIN
diode radiodetector from BioScan, a DGU-20A degasser, two LC-20AB pumps, and SPDM20A photodiode array detector and a SPD-M20A autosampler using reversed phase
columns: (1) semipreparative: Luna 5 Uμ C18, 100 Å, 250 × 10 mm, (Phenomenex,
Torrance, CA) (2) analytical: Luna 5 Uμ C18, 100 Å, 250 × 4.6 mm, (Phenomenex,
Torrance, CA) (3) semipreparative: Nova-Pak 6 Uμ C18, 60 Å, 300 × 7.8 mm, (Waters,
Milford, MA). Different gradient solvent systems were applied: (A) 20% – 80% MeCN in
water in the presence of 0.1% trifluoroacetic acid (TFA) in 20 min with a flow of 5 mL/min;
(B) 20% – 80% MeCN in water with 0.1% TFA in 20 min with a flow of 1.5 mL/min; (C)
5% – 40% EtOH in water in 5 min, 40% EtOH in water from 5–15 min with a flow rate of 3
mL/min.

$watermark-text

Chemistry
Syntheses of cold reference compounds 2 to 5 are presented on Scheme 1.
2-((Tert-butyldimethylsilyl)ethynyl)-6-fluoropyridine (2)

$watermark-text

To a degassed solution of tert-butyl(ethynyl)dimethylsilane (190 mg, 1.30 mmol) in
triethylamine (Et3N, 0.6 mL) and DMF (2 mL) was added CuI (50 mg, 0.26 mmol). To a
second degassed solution of 2-bromo-6-fluoropyridine (200 mg, 1.10 mmol) in DMF (4 mL)
was added Pd(PPh3)4 (15 mg, 0.013 mmol). Both mixtures were stirred for 5 min and then
combined and allowed to react at RT for 24 h before saturated aqueous NH4Cl (7 mL) was
added. The resulting solution was then extracted with diethylether (Et2O, 3 × 20 mL). The
combined organic layers were washed with water (2 × 20 mL) and brine (20 mL) before
drying over Na2SO4. Careful evaporation resulted in a brown oily residue. Purification by
silica gel column chromatography utilizing pentane/Et2O (95:5) gave 2 (105 mg, 40%) as a
colorless oil that formed white crystals at 4 °C. Rf = 0.8 (Pentane : ethyl acetate; 9:1). 1H
NMR (500 MHz, CDCl3): δ 7.71 (q, J = 7.7 Hz, 1H), 7.33 (d, J = 6.5 Hz, 1H), 6.88 (dd, J
=1.3, 2.5 Hz, 1H), 0.99 (s, 9H), 0.20 (s, 6H). 13C NMR (500 MHz, CDCl3): 162.9 (d, J =
241.2 Hz), 141.0 (d, J = 12.7 Hz), 125.0 (d, J = 3.9 Hz), 124.8 (d, J = 54.22 Hz), 109.6 (d, J
= 36.9 Hz), 102.9, 95.0, 26.1, 16.7, 1.0. 19F NMR (500 MHz, CDCl3) : δ −65.17. MS m/z :
236.21 (M + H)+.
2-Ethynyl-6-fluoropyridine (3)
To a solution of 2 (30 mg, 0.12 mmol) in dry tetrahydrofuran (THF, 2.5 mL) was added
tetrabutylammonium fluoride (TBAF) trihydrate (120 mg, 0.38 mmol). After stirring the
reaction mixture for one hour at RT, water (10 mL) was added. This mixture in water/THF
(1:4) was used without further purification for the synthesis of the fluorinated reference

Bioconjug Chem. Author manuscript; available in PMC 2013 August 15.

Daumar et al.

Page 5

$watermark-text

peptides. For analytical purposes, compound 3 was purified by semipreparative HPLC using
the column 1 and the gradient solvent system A. The retention time of compound 3 was 11.2
min. Due to the volatility of the product and the small scale of the synthesis, concentration
of the product was achieved using a C18 light cartridge (Waters) preconditioned with 5 mL
of EtOH, followed by 5 mL of water. The combined fractions were diluted with water and
passed over the cartridge. Pure product 3 was eluted with CDCl3. 1H NMR (500 MHz,
CDCl3): δ 7.76 (q, J = 7.8 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 6.94 (dd, J = 2.7, 2.9 Hz, 1H),
3.19 (s, 1H). 13C NMR (500 MHz, CDCl3): δ 162.9 (d, J = 237.8 Hz), 141.2 (d, J = 7.2 Hz),
125.4 (d, J = 96.37 Hz), 125.0 (d, J = 36.9 Hz), 110.2 (d, J = 36.8 Hz), 81.3, 78.3. 19F NMR
(500 MHz, CDCl3): δ −65.30. MS m/z 121.89 (M + H)+. HRMS calcd for C7H5NF,
122.0407; found, 122.0406.
6-(4-(6-Fluoropyridin-2-yl)-1H-1,2,3-triazol-1-yl)hexanoyl-D-WT-pHLIP (Fpyrtriazolo-D-WTpHLIP, 4)

$watermark-text

100 μL (0.01 mmol) of a freshly prepared solution of Cu(II) acetate (18 mg/mL) and 200 μL
(0.02 mmol) of a fresh (+)-sodium L-ascorbate solution (20 mg/mL) in water were mixed in
a sealed vial under argon. To the yellow mixture was added a solution of azidohexanoyl-DWTpHLIP (N3(CH2)5CONH-ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTGCO2H) in EtOH (5 mg in 300 UL, 0.0012 mmol). Further addition of 2.7 μL of the solution
of 3 (0.025 mmol) in water/THF (1:4) was followed by stirring of the reaction mixture at RT
for 70 h before MeCN (3 mL) and water (3 mL) were added. The product was purified using
semipreparative HPLC (column 1, solvent gradient system A): two conformational isomers
(4a, 4b) of Fpyrtriazolo-D-WTpHLIP were obtained with tR1 = 18.7 min and tR2 = 20.1 min,
respectively. HPLC analysis indicated that the overall chemical purity of the compound 4
(4a + 4b) is >98%. Calculated monoisotopic mass for Fpyrtriazolo-D-WTpHLIP
(C206H301FN48O58S): 4426.18. 4a: found, MS (MALDI) m/z = 4426.65, 4b: found, MS
(MALDI) m/z = 4426.56.
6-(4-(6-Fluoropyridin-2-yl)-1H-1,2,3-triazol-1-yl)hexanoyl-L-K-pHLIP (Fpyrtriazolo-L-KpHLIP, 5)
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This compound was prepared in an analogous way to compound 4. The mixture containing
the azidohexanoyl-L-K-pHLIP (N3(CH2)5CONHACEQNPIYWARYAKWLFTTPLLLLKLALLVDADEGTG-CO2H, 7.7 mg, 1.18 μmol)
was stirred at RT for 48 h. Purification of the product was achieved by semipreparative
HPLC on column 1 using the gradient solvent system A: tR = 15.7 min; 99% purity.
Calculated monoisotopic mass for peptide 5 (C210H315FN50O54S): 4452.31; found, MS
(MALDI) m/z = 4452.724.
Radiochemistry
Radiosyntheses of [18F]-3 to [18F]-5 are presented on Scheme 2.
Radiosynthesis of [18F]-3
[18F]-fluoride (1480 – 2220 MBq) was obtained via the 18O(p,n)18F reaction of 11-MeV
protons in an EBCO TR-19/9 cyclotron using enriched 18O-water. QMA light cartridges
(Waters) preconditioned with 0.5 M K2CO3 (5 mL) and water (5 mL) were used for trapping
of 18F− from the aqueous solution. In order to elute 18F− from the cartridge into a sealed 5
mL reaction vial, 1 mL of Kryptofix K222 solution (Kryptofix K222, 2.5 mg; K2CO3, 0.5 mg
in MeCN/water (3:1)) was slowly passed through the cartridge. The solvents were
evaporated at 110 ºC under vacuum in the presence of slight inflow of argon gas. After
addition of MeCN (1 mL), azeotropic drying was achieved under vacuum and with a slight
argon inflow. For the complete removal of water traces, the procedure was repeated twice. A
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solution of the corresponding precursor 6 (Anichem), 1.5 – 2 mg in 200 μL of dry DMSO,
was added to the Kryptofix complex and the reaction mixture was heated at 130 ºC for 10
min before 1 mL of water and 0.4 mL of MeCN were added (total injection volume 1.6 mL).
Purification by semipreparative HPLC was carried out using the reversed phase column 3
with the gradient solvent system C: the product was eluted with the same retention time as
the cold standard 3: tR = 9.2 min. Under the conditions used, the bromo precursor 6 has a
retention time of 10.8 min. Identification of [18F]-3 was achieved by co-injection with the
reference 3 on the reversed phase column 1 and the solvent system A: tR = 10.2 min (Figure
2A).

$watermark-text

Radiosynthesis of [18F]-4

$watermark-text
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Stock solutions of copper (II) acetate (18 mg/mL) and (+)-sodium L-ascorbate (20 mg/mL),
respectively, were freshly prepared. A v-shaped 4 mL HPLC vial (MT-ITTM, Prominence,
SHIMADZU) was equipped with a stir bar, sealed and set under argon before 30 μL of the
Cu(II) acetate solution and 60 μL of the (+)-sodium L-ascorbate solution were mixed. The
prosthetic group [18F]-3 (150 – 500 MBq) was directly collected from the HPLC into the
prepared 4 mL HPLC vial (V = 1.2 – 1.6 mL). A solution of azidohexanoyl-D-WT-pHLIP
(N3(CH2)5CONH-ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTG-CO2H, 1
mg, 0.2 μmol) in EtOH (150 μL) was added and the mixture was heated at 70 °C for 5 – 10
min. After addition of MeCN (100 μL), purification of the product was achieved using
semipreparative HPLC on reversed phase column 1 with solvent system A (total injection
volume 1.5 – 2.0 mL). Two main radioactive peaks were eluted with the same retention time
as the cold reference compounds 4a and 4b that are conformational isomers. HPLC analysis
indicated that the overall radiochemical purity of the compound 4 (4a + 4b) is >98%. The
radiolabeled peptide could not be isolated from the peptide starting material resulting in
lowered apparent specific activity. Only [18F]-4a, obtained in MeCN/water (3:1, 0.1%
TFA), was used for in vivo evaluation. After dilution with 7 mL of water, the solution was
passed over a C18 light Sep Pak cartridge (Waters), preconditioned with 5 mL of EtOH
followed by 5 mL of water. The cartridge was washed with further 3 mL of water in order to
remove traces of MeCN and TFA and the trapped [18F]-D-WT-pHLIP ([18F]-4a) was eluted
with 0.5 – 1 mL of EtOH. Identification of [18F]-4a was achieved by comparison of the
retention time with the cold reference compound 4 eluted with identical retention time under
the same HPLC conditions but injecting only 50 μL of the collected solution for analysis.
After evaporation of the solvent under vacuum and a slight argon inflow, which was
completed within 6–8 minutes, the product was formulated in saline with 3% ethanol for
injection.
Radiosynthesis of [18F]-5
The radiosynthesis and purification were achieved in an analogous way to [18F]-4. For the
formulation of an injectable solution of [18F]-5, a cartridge purification step was performed
as described above. The product was eluted with 1.5 mL of acidified EtOH containing
0.02% 2N HCl and the solvent was removed under vacuum and a slight argon inflow.
[18F]-5 was formulated in phosphate buffer for injection after addition of 50 μL of 0.1 N
NaOH for neutralization. Identification of [18F]-5 was achieved by comparison of the
retention time with the cold reference compound 5 eluted with identical retention time under
the same HPLC conditions.
Determination of the lipophilicity of [18F]-4 and [18F]-5 (logDpH7.4)
As described by Wilson et al.29 for the shake flask method, phosphate buffer (pH 7.4)
saturated octanol (500 μL) and octanol saturated phosphate buffer (500 μL) were added to a
microcentrifuge tube (1.5 mL, Eppendorf). Following the addition of 10 μL of the
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radiotracer solution (approximately 37 kBq), the samples were first vortexed and then
shaken for 15 min. For phase separation, the samples were centrifuged at 2348 rcf for 5 min.
50 μL of each layer were withdrawn carefully from each phase and pipetted into
microcentrifuge tubes (Eppendorf) for measurement of the distribution of the activity with a
gamma-counter (Wizard2, Perkin Elmer). The experiment was performed in quintuplicate.
In vitro stability test

$watermark-text

For the determination of the in vitro stability of 18F-labeled pHLIP analogues, 20 μL of the
model peptide [18F]-D-WT-pHLIP ([18F]-4) in EtOH were added to both human and murine
plasma (380 μL) and incubated at 37 °C. After 60 and 120 min, aliquots of 180 μL were
removed and added to an equal amount of MeCN for precipitation of the present proteins.
After 5 min of centrifugation (21130 rcf), 4 °C), the supernatant was analyzed under
semipreparative HPLC conditions as described for the purification of the radiolabeled
peptides.
Tumor cell culture

$watermark-text

Human prostate cancer cell lines LNCaP and PC-3 from the American Tissue Culture
Collection (ATCC, Manassas, VA, USA) were cultured in a 5% CO2 atmosphere at 37 °C.
LNCaP cells were cultured in RPMI 1640 medium containing 10% fetal calf serum (FCS), 2
mM L-glutamine, 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate and
100 U/mL of penicillin and streptomycin. PC-3 cell were cultured in F-12 Kaighn’s medium
containing 10% FCS, 2 mM L-glutamine, 1.5 g/L sodium bicarbonate and 100 U/mL of
penicillin and streptomycin. Cells were trypsinized in the absence of magnesium or calcium
ions using a cocktail of 0.25% trypsin and 0.53 mM EDTA in Hank’s buffered salt solution.
LNCaP and PC-3 tumor xenografts

$watermark-text

Male athymic mice (NCRNU-M, 20–25 g) were obtained from Taconic Farms, Inc (Hudson,
NY, USA) and were kept in the MSKCC vivarium for one week before any experimental
handling was performed. The animals were allowed free access to water and food and all
animal care and experimental procedures were approved by the Institutional Animal Care
and Use Committee (IACUC). LNCaP and PC-3 tumor xenografts were induced on the right
and the left shoulder of each mouse, respectively, by subcutaneous injection of the
corresponding cell suspension in Matrigel (BD, Collaborative Biomedical Products, Inc.,
Bedford, MA, USA) and media (1:1) containing 5.0 × 106 – 107cells (viability > 90%) per
injection (200 μL). All procedures were carried out under anesthesia (1.5% isoflurane).
Because of the slow rate of growth of the LNCaP tumors, these tumors were implanted 14
days prior to the PC-3 tumor implantation to have similarly sized tumors for the imaging and
biodistribution studies. Palpable tumors of similar size developed after 4 to 5 weeks after the
initial tumor xenograft induction.
Small-animal PET imaging studies
PET imaging studies were conducted on a microPET Focus 120 rodent scanner (Concorde
Microsystems). Dual tumor bearing mice (n = 4) with LNCaP tumor (right shoulder, V =
100 – 200 mm3) and PC-3 (left shoulder, V = 100 – 200 mm3) were administered [18F]-4
[160–170 μCi (5.9 – 6.3 MBq)] in 200 μL formulated solution (3% EtOH in saline) and
control peptide [18F]-5 [260 μCi (9.8 MBq)] in 200 μL formulated solution (Phosphate
Buffered Saline) via tail vein injection. Approximately 3 min prior to the PET scan, mice
were anesthetized by inhalation of 2% isoflurane (Baxter Healthcare, Deerfield, IL, USA)/
oxygen gas mixture and placed on the bed of the scanner while anesthesia was maintained
using 1.5% isoflurane/gas mixture. PET data for each mouse were recorded via a 15-min
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static acquisition 2 and 4h post injection (p. i.). For the static images a minimum of 20
million coincidence events were detected.
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An energy window of 350–700 keV and a coincidence timing window of 6 ns were used.
Data were sorted into two-dimensional histograms by Fourier re-binning, and transverse
images were reconstructed by filtered back-projection into a 128×128×63 (0.72×0.72×1.3
mm) matrix. The images were normalized to correct for non-uniformity of response of the
PET, dead-time count losses, positron branching ratio and physical decay to the time of
injection, but no attenuation, scatter or partial-volume averaging correction was applied. The
measured reconstructed spatial resolution for the Focus 120 is approximately 1.6 mm in full
width at half maximum at the center of the field of view. The counting rates in the
reconstructed images were converted to percent of injected dose per weight (%ID/g) by use
of a system calibration factor derived from the imaging of a mouse-sized water-equivalent
phantom containing 18F. Images were evaluated by region-of-interest (ROI) analysis using
ASIPro VM software (Concorde Microsystems).
Combined histological/autoradiographic analysis

$watermark-text

After the completion of the last imaging session, vascular perfusion marker Hoechst 33342
(15 mg/kg in 0.2 mL of sterile saline) was administered via the tail vein catheter. Series of
contiguous fresh-frozen tumor sections of 10 μm thickness were cut and exposed to a
phosphor-imaging plate (Fujifilm BAS-MS2325, Fuji Photo Film, Japan) for an appropriate
length of time at −20 °C. Digital images of radioactivity distribution at 50 μm resolution
were obtained. The same sections were subsequently used for immunofluorescence imaging
of Hoechst 33342, and finally stained with H&E. Autoradiographic and histological images
were registered using Adobe Photoshop CS3 software.
Postmortem biodistribution studies
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Dual tumor bearing mice (LNCaP and PC-3 tumors) were randomized before the
experiment. Only mice with palpable tumors (V = 0.5 – 1.5 cm3) were utilized. In order to
investigate the biodistribution of radioactivity upon [18F]-D-WT-pHLIP ([18F]-4) injection,
the tracer [~ 39 μCi (1.4 MBq), 15 nmol, 150 – 250 μL] was administered intravenously to
the mice (n = 4 per time point, 16 – 24 g). Four mice were euthanized at 2 and 4 h post
injection (p. i.), respectively. The blood was collected immediately followed by quick
removal of the tumors. The lung, liver, heart, kidneys, spleen, bone, muscle, stomach, small
intestines (SI), large intestines (LI) and testes were taken as well. The individual tumors and
further organs were weighed and the radioactivity in each sample was measured in the
gamma counter. Activity concentrations were calculated as percentage injected dose per
tissue weight. (%ID/g wet tissue).
As a negative control, a formulated solution of [18F]-5 [55 μCi (2 MBq), 3.5 nmol)] was
administered to a further group of dual tumor bearing mice (n = 4, 19 – 22 g). These mice
were euthanized at 2 h p. i. and biodistribution performed as above.

RESULTS AND DISCUSSION
Recently, the CuAAC “click reaction” has attracted increasing interest for the 18F-labeling
of peptides, mainly because of the recent development of novel [18F]-prosthetic groups and
efficient protocols for this type of chemistry.16, 17, 30 However, the feasibility of such
methods for the synthesis of large [18F]-peptides (MW > 2000 Da) has yet to be proven.
Indeed, the preparation of an 18F-labeled αvβ6 specific 20 amino acids peptide by Hausner
et al. in 2008 is the only successful report,13 which demonstrates the challenge of labeling
large peptides efficiently without affecting their integrity.
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We experienced numerous difficulties during our first attempts to synthesize 18F-labeled
WT-pHLIP via CuAAC using a previously described [18F]fluoro-PEG-alkyne. Indeed, even
though such a prosthetic group has been used successfully for the radiolabeling of RGD
constructs,18 no “click coupling” with azido-derivatized pHLIP analogues was observed in
the standard CuAAC conditions that we used (Cu(II) acetate/(+)-sodium L-ascorbate in
H2O/CH3CN 1:1). We were therefore interested in the development of a novel fluorinated
prosthetic group and a corresponding synthetic procedure (Scheme 1), suitable for the
radiolabeling of large peptides. We chose Fluoropyridinealkyne 3 because of the
commercial availability of the corresponding bromo-precursor 6, its UV-detectability, and
the fact that 2-[18F]fluoropyridines were shown to display high in vivo stability.31
Moreover, the small size of 3 was expected to have a very limited impact on the
pharmacokinetic of peptides as large as pHLIP.
Radiochemistry

$watermark-text

[18F]-3 was prepared in one step by nucleophilic fluorination of the corresponding bromo
precursor 6 (Scheme 2) using Kryptofix and K2CO3. Optimized conditions (DMSO, 10 min,
130 °C) led to [18F]-3 in RCYs of 27.5 ± 6.6% (n = 11) decay corrected (d. c.), with
conversion rates between 70 and 90%. This high labeling efficacy was not translated into
higher RCYs because a loss of radioactivity was systematically observed during the transfer
to the HPLC, presumably due to the volatility of [18F]-3. Although a distillation-based
purification might allow for higher yields, like those obtained with volatile
[18F]fluoroalkynes prosthetic groups,19 it would also introduce MeCN, which in our case
was not favorable for the subsequent “click” reaction. Instead, technical improvements or
pH adjustments could potentially minimize the effect of the pyridine alkyne volatility issue.
Our HPLC purification has as principal advantage to afford [18F]-3 in high radiochemical
purity (RCP > 98%, Figure 2A) in a mixture of ethanol and water, which appeared to be a
perfectly suitable solvent system for the CuAAC with pHLIP. Indeed, full incorporation of
[18F]-3 was achieved within 10 min at 70 °C as demonstrated by the HPLC chromatograms
on Figure 2B and 2C, where no unreacted material [18F]-3 was detected.
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The two peaks observed on Figure 2B are due to acidic HPLC conditions, which promotes
the formation of two pH-dependent conformational isomers (4a and 4b). When either of the
peaks were collected separately and reinjected, we observed two peaks in HPLC indicating
that these are same chemical species. This fact has also been confirmed by HPLC-MS. No
dimerization of peptide (through cysteine-cysteine disulfide linkage) was observed. It is also
interesting to note that conformational isomers were only observed in the case of WT-pHLIP
(Figure 2B), which reflects the non acidity-dependent behavior of K-pHLIP (Figure 2C).
Figure 2 also reveals that the radiolabeled peptides [18F]-4 and [18F]-5 could not be
separated from the azido-derivatized starting materials. Consequently, the apparent specific
activities were low (0.1 – 1 GBq/μmol), which should not question the use of [18F]-pHLIP
as an efficient PET tracer anyway. Indeed, given the mechanism of pHLIP insertion across
the cell membrane, the number of insertion sites is theoretically unlimited wherever an
acidic microenvironment is present,7 as opposed to receptor based targeting systems.32
Considering the size and the complexity of the [18F]-pHLIP analogues, the detailed
radiochemical data obtained with [18F]-4 and [18F]-5 (Table 1) show the high efficacy of our
novel strategy using [18F]-3. Total RCYs of up to 20% could be achieved with respect to the
starting amount of [18F]-fluoride activity in a short synthesis time (≤ 85 min) and in one
step, whereas several of the UV-detectable prosthetic groups that were used for peptide
labeling were produced after multi-step radiosyntheses.22, 23, 33 The total radiochemical
yields also reflects that some radioactivity was lost during the transfers and on the HPLC,
which leads to reduced overall yields. In our preparative HPLC conditions we never
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observed any unreacted [18F]-3 or other byproducts in the reaction. Although better yields
were reported with small-size peptides,16 the CuAAC for was never achieved in such high
yields with large peptides. By comparison, Hausner et al. radiolabeled a 20 amino acid
peptide via “click” reaction in yields below 10%.13 Finally, our novel 18F-labeling protocol
was performed with low amounts of copper, and a minimum of 1 mg peptide starting
material was necessary to achieve complete incorporation of [18F]-3, which is in line with
previously reported 18F-”click” reactions on larger peptides.13

$watermark-text

For the characterization of the novel 18F-labeled pHLIP analogues, a logDpH7.4
determination was carried out (Table 1). [18F]-4a and [18F]-4b eluted from the HPLC
system with different retention times and relative lipophilicity, exhibited the same logDpH7.4
of −0.7 presumably due to isomerization and formation of the same equilibrium state at pH
7.4. [18F]-5 was eluted from the HPLC system with shorter retention time, and it
accordingly displayed a logDpH7.4 of −1.30 ± 0.03. It is well accepted that most of the [18F]prosthetic groups (Figure 1) lead to more lipophilic 18F-labeled peptides, especially as the
“click” approach involves the formation of a lipophilic triazole ring, often considered as a
surrogate for the amide bond.16,34 Although a similar effect is expected with the use of
[18F]-3, the small size of the prosthetic group and the triazole ring should only have a
limited impact on the pharmacological properties of future investigated peptides.
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The stability of the [18F]-prosthetic group in the [18F]-peptide construct is important in
terms of clearance and metabolism. In particular, in vivo radio-defluorination is easily
detectable because of the related bone uptake of radioactivity.32 Therefore, [18F]-4a, as a
prominent pHLIP analogue was first subjected to an in vitro stability test in human and
murine plasma at 37 °C. The tracer displayed a good stability: after 60 min, 80% and 100%
of the parent tracer remained intact in human and murine plasma, respectively ; 65% and
85% were still present after 120 min. The degradation products were more hydrophilic and
displayed retention times (tR) suggesting potential peptide fragments. [18F]-Fluoride is very
hydrophilic and an elution from the HPLC column within the first 3 min is expected.
However, no radioactive peaks were detected during the first 10 min. The fact that peptides
derived from D-amino acids were shown to display higher in vivo stability,35, 36 and the
good in vitro stability of the D-WT-pHLIP analogue, [18F]-4a, encouraged the in vivo
evaluation of the novel peptide tracers.
PET imaging studies

$watermark-text

In order to prove the ability of [18F]-4a to target acidity, we chose two prostate carcinoma
tumor models, LNCaP and PC-3. Indeed, as determined by magnetic resonance, Vavere et
al. reported a significantly more acidic average pHe for LNCaP tumors when compared with
the PC-3 tumors.9 Therefore, we were hopeful that this difference could be observed with
PET following [18F]-4a administration.
As a matter of fact, the LNCaP tumor could be clearly visualized at both time points (Figure
3) and exhibited a radioactivity accumulation of 8.3 ± 1.5 and 8.5 ± 1.3%ID/g at 2 and 4 h p.
i., respectively. The PC-3 tumor showed lower radioactivity accumulation of 4.2 ± 0.4 to 5.4
± 0.5%ID/g at 2 and 4 h p.i, respectively, and was poorly visualized. The lower uptake is a
good indication for the successful application of the pHLIP principle for PET imaging of
acidic tumors. Another indication for the specificity of the pHLIP was the lack of any tumor
accumulation observed with the negative control peptide [18F]-K-pHLIP (Figure 3).
The MR studies reported by Vavere et al. determined the total volume average pHe in the
tumors, but the heterogeneity of the tumor microenvironment suggests the formation of
acidic and non-acidic areas in tumors. Accordingly, the PET images acquired after [18F]-4a
administration displayed a heterogeneous distribution of the tracer in the tumor since hot
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spots within the LNCaP tumor could be visualized, indicating the specific enrichment of
pHLIP analogues in acidic regions. Therefore, following PET imaging at 4h p. i., tumors
were excised, sectioned and evaluated by digital autoradiography for 18F-distribution. This
distribution was subsequently compared to the distribution of the vascular perfusion marker
Hoechst 33342 using the same section. A clear pattern of higher 18F uptake in tumor regions
lacking vascular perfusion was observed (Figure 4). Previous studies have shown that tumor
regions with low vascular perfusion are associated with low pO2 and anaerobic glycolysis,
resulting in lactate accumulation and reduced pH.37 The accumulation of [18F]-4a in tumor
regions lacking vascular perfusion is consistent with the proposed mechanism of pHLIP
accumulation, and corroborates the specificity underlying the heterogeneous tumor
distribution observed in the PET imaging.
For both tracers, the PET images exhibited the highest radioactivity concentrations in the
liver indicating that [18F]-4a and [18F]-5 are mainly excreted via the hepatobiliary system.
Little radioactivity accumulation was detected in the bone in all PET imaging studies
performed with the [18F]-pHLIP radiotracer that were radiolabeled using our novel [18F]labeling protocol, pointing to a high in vivo stability of the [18F]-prosthetic groups. The high
activity observed in the liver might preclude the use of the tracer for imaging tumors near
the liver.
Biodistribution
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Biodistribution studies were performed with [18F]-4a and [18F]-5 in mice with dual PC-3
(left) and LNCaP (right) tumors on the shoulders. Based on our preliminary imaging studies
we chose the 2 and 4 h time points for the biodistribution study. Figure 5 shows the
distribution of radioactivity in mice of [18F]-4a at 2 and 4 h p.i. and of [18F]-5 at 2 h. For
[18F]-4a, the highest accumulation of radioactivity in LNCaP tumors was observed at 4 h
p.i.. The uptake in PC-3 tumors was much lower at both time points. At 4 h p.i. LNCaP
tumors had uptake of 8.0 ± 0.7 %ID/g as compared to PC-3 tumors which had uptake 5.3 ±
0.7 %ID/g. These results are in line with our earlier publication9 with [64Cu]-DOTA-pHLIP
(all L amino acids) and with PET imaging studies.
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The highest accumulation of radioactivity at both time points was detected in the liver (32.5
± 4.3%ID/g and 34.9 ± 5.8%ID/g at 2 and 4 h p. i., respectively), followed by the kidneys.
As expected with large hydrophobic peptides the blood clearance was slow. [64Cu]-pHLIP
shows highest accumulation in LNCaP tumors at 1 h p. i. (4.5 ± 1.7%ID/g) and highest
tumor to blood ratio at 24 h p.i.9.
The tumor-to-tissue ratios for [18F]-4a and [18F]-5 are shown in Table 2. The tumor
(LNCaP)-to-liver and the tumor (LNCaP)-to-kidney ratios are 0.2 and 0.3, respectively, both
at 2 and 4 h. From our limited biodistribution studies it is difficult to differentiate between
excretory and metabolic factors contributing to these high values. As shown in table 2, the
negative control peptide [18F]-5 exhibits similar ratios in liver and kidney. It can be
hypothesized that the activity in these organs is due to excretion rather than metabolism. The
tumor–to-muscle ratio of 4.5 measured at 2 h p. i. with [18F]-4a in comparison to 0.4 with
[18F]-5, demonstrates we are specifically targeting the tumor with [18F]-4a and is not a
result of non-specific accumulation. The tumor-to-muscle ratio is even higher at 4 h p. i.
with a value of 5.7. These studies clearly demonstrate that this click approach with
prosthetic group 3 has no negative impact on the biological properties of pHLIP.
Additionally, higher %ID/g values in LNCaP tumors as compared to the PC-3 tumor
indicate that the accumulation of the tracer reflects acidity of the tissue.
[18F]-pyridines labeled at ortho-position to the nitrogen have been reported to be stable
against in vivo defluorination.31 However, we observe some bone uptake with [18F]-5 (1.31
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± 0.63 %ID/g) and [18F]-4a (4.14 ± 1.12 %ID/g) 2h p. i.. In comparison, [18F]Fluoropentyne based prosthetic group shows very minimal bone uptake (0.39 %ID/g at 1h
p.i.). In our case, it is unclear whether the uptake is result of defluorination or specific
accumulation, because the two peptides radiolabeled wth same prosthetic group show
different bone uptake values.

CONCLUSION
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We have extended the use of the CuAAC “click chemistry” with the development of 2ethynyl-6-[18F]fluoro-pyridine as a new prosthetic group suitable for the 18F-labeling of
large peptides. This approach should be widely applicable and was shown to be efficient for
the radiolabeling of pHLIP analogues with a molecular weight over 4000 Da. Two 18Flabeled analogues were injected in mice in order to acquire the first in vivo [18F]-pHLIP
data. The WT-pHLIP construct showed good in vitro stability and only mild in vivo
defluorination was observed in both cases. A milestone in the development of a 18F-labeled
pHLIP tumor imaging agent was achieved, as the use of [18F]-3 will allow for the fast
production and evaluation of second generation pHLIP analogues, designed for higher
accumulation in the tumors and faster clearance from non-target tissues.
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Figure 1.

Examples of [18F]-labeled prosthetic groups for the CuAAC “click” reaction with
functionalized peptides and proteins.
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Figure 2.

HPLC chromatograms with radio and UV-traces (UV traces were recorded at 254 nm and
retention times are given with respect to the radiotrace): (A) co-injection of compound 3 and
[18F]-3 with tR = 10.4 min on column 1; (B) purification of [18F]-4a and −4b after 5 min at
70 °C with tR = 18.7 min and tR = 20.2 min, respectively; (C) purification of [18F]-5 after 5
min reaction at 70 °C (tR = 15.8 min). HPLC chromatograms were recorded utilizing
column 1 applying elution conditions A.
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Figure 3.

Representative coronal PET images of mice bearing LNCaP (Right) and PC-3 (Left) tumors
injected with [18F]-4 (A) and [18F]-5 (B).
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Figure 4.

$watermark-text

Combined histological/autoradiographic analysis obtained after [18F]-4 injection (4h p. i.).
Data from a single 10 μm frozen section obtained from a LNCaP tumor. H&E staining
(panel A), the vascular perfusion marker Hoechst 33342 (blue, panel B) and autoradiograph
of radioactivity distribution (panel C) are shown. Panel D shows co-registration of
autoradiograph (pseudo-color green) overlaid with Hoechst 33342 (blue). Panel E contains a
high-magnification region from the image shown in Panel D. Scale bar = 1mm.
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Figure 5.

Biodistribution of [18F]-4 and [18F]-5 at 2 and 4 h p. i. with uptake values expressed as %ID/
g.
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Scheme 1.

Synthetic route yielding the non-radiolabeled reference compounds 3 to 5.
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Scheme 2.
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Radiosynthesis yielding radiolabeled products [18F]-3 to [18F]-5.
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≥ 98

---

([18F]-5)

[18F]-D-WT-pHLIP ([18F]-4b)

[18F]-L-K-pHLIP

≥ 95

[18F]-D-WT-pHLIP ([18F]-4a)

RCP [%]

5 – 13

13.6 ± 6.0

Total RCY [%]

0.1 – 0.8

---

0.1 – 1.0

Specific activity (EOS) [GBq/μmol]

85

Total preparation time [min]

− 1.30 ± 0.03

− 0.70 ± 0.20

− 0.70 ± 0.04

logDpH7.4

Analytical data determined for radiolabeled peptides [18F]-4a, [18F]-4b (n = 4) and [18F]-5 (n = 3) after semipreparative HPLC purification.
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Table 2
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LNCaP tumor-to-tissue ratios determined upon biodistribution studies with the tracers administered to tumor
bearing mice.
Tumor to Tissue ratio

[18F]-4
2 h p. i.

[18F]-4
4 h p. i.

[18F]-5
2 h p. i.

Tumor/blood

0.2

0.4

0.1

Tumor/muscle

4.5

5.7

0.4

Tumor/liver

0.2

0.2

0.2

Tumor/kidney

0.3

0.3

0.4
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